{
    "nctId": "NCT01325558",
    "briefTitle": "A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors",
    "officialTitle": "A Phase I, Open-Label, Multi-center, Competitive Enrollment and Dose-escalation Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advanced Malignant Neoplasm, Malignant Solid Tumour",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Maximum Tolerated Dose (MTD) of ALT-836 in combination with gemcitabine",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed\n* Locally advanced or metastatic non-hematologic malignancies\n* Measureable\n* Refractory to standard therapies or single agent gemcitabine is indicated as a standard treatment option\n\nPRIOR/CONCURRENT THERAPY:\n\n* No concurrent radiotherapy, chemotherapy, immunotherapy or other investigational agents\n* Must have recovered from side effects of prior therapies\n\nPATIENT CHARACTERISTICS:\n\nLife expectancy\n\n* \\> 12 weeks\n\nPerformance Status\n\n* ECOG 0 or 1\n\nBone Marrow Reserve\n\n* Absolute Neutrophil count (AGC/ANC) \u2265 1,500/uL\n* Platelets \u2265 100,000/uL\n* Hemoglobin \\> 9 g/dL\n\nRenal Function\n\n* Calculated Glomerular filtration rate (GFR) \\> 59mL/min/1.73M\\^2\n\nHepatic Function\n\n* Total bilirubin \u2264 1.5 X ULN\n* AST, ALT, and ALP \u2264 3 X ULN or \u2264 5.0 x ULN, if liver metastasis exists\n* PT INR \u2264 1.5 X ULN\n\nCardiovascular\n\n* No history of clinically significant vascular disease\n* No New York Heart Association (NYHA) Class \\> II heart failure\n\nHematologic\n\n* No history of bleeding disorders\n* No evidence of bleeding diathesis or coagulopathy\n* No presence of clinically significant hemoptysis or hematuria, presence of serious non-healing wound or ulceration, or signs of other bleeding\n* No evidence of a tumor invasion of any major blood vessel\n* No trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within two months of study entry\n\nSurgery/Procedures\n\n* No major surgery or open biopsy within 28 days before drug infusion or evidence of active bleeding postoperatively\n* No plan for any major surgery during treatment period\n* No presence or requirement of an epidural catheter or lumbar puncture within 48 hours prior to each dose of study treatment\n* No anticipation of receiving an epidural catheter or a lumbar puncture within 48 hours after each dose of study treatment\n\nExcluded Medications or Treatment Regimens\n\n* Unfractionated heparin of \\> 15,000 units/day within 8 hours prior to each dose of study treatment\n* Low-molecular weight heparin at a higher dose than recommended for prophylactic used or required within 20 hours prior to each dose of study treatment\n* Warfarin used or required within 48 hours prior to each dose of study treatment and the prothrombin time (INR) exceeded the upper limit of normal range\n* Direct thrombin inhibitors or Xa inhibitors\n* Acetylsalicylic acid used or required within 72 hours prior to each dose of study treatment\n* Clopidogrel bisulfate used or required within 48 hours prior to each dose of study treatment\n* Anticipated requirement for anti-platelet or anti-coagulant agents excluding non-aspirin NSAID within 48 hours following study treatment infusion\n\nOther\n\n* No active systemic infection requiring parenteral antibiotic therapy\n* No history of or presence of a CNS disease\n* No history of allergic reactions to compounds of similar chemical or biologic composition\n* Not HIV positive\n* No women who are pregnant or nursing\n* A negative serum pregnancy test if female\n* Patients, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study\n* No history of significant renal, endocrinologic, metabolic, immunologic or hepatic disease\n* No evidence of psychiatric illness/social situations\n* Other illness that in the opinion of the investigator would exclude the patient from participating\n* Must provide informed consent and HIPAA authorization and comply with protocol-specified procedures and follow-up evaluations",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}